“Green light” to Lilly’s monoclonal antibody to migraine

2018-11-28T17:21:25+00:0028/11/2018|Categories: Industry, News|Tags: , , , , , , , |

Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab ( Emgality ) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month . Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes of migraine, blocks its function Administered with a month subcutaneous injection which can be applied to the patient with a pen or pre-filled syringe. In all three clinical trials, galcanezumab has shown significantly reducing the monthly average of migraine days and an improvement in functionality versus placebo. "Migraine is [...]

Novartis’ Migraine prevention therapy is closer to being approved

2018-06-04T13:44:50+00:0004/06/2018|Categories: Industry, News|Tags: , , , |

Friday, June 1, 2018, at 15:45 Novartis has announced that the European Medicines Agency (EMA) Committee on Human Use Medicines (CHMP) has recommended Aimovig (erenumab) approval to prevent migraine in adults suffering at least 4 days of migraine per month. The World Health Organization (WHO) has mentioned migraine as one of the top ten causes of years of disability worldwide. Aimovig is the first treatment of its kind specifically developed to prevent migraine, blocking the peptide related to the calcitonin gene (CGRPR), which plays an essential role in the pathology of migraine. If approved, Aimovig will be administered once a month [...]

We and our partners use cookies, to collect browsing data to give you the best online experience and to personalize the content, play multimedia content, interact with social networks and perform browsing analytics. If you continue browsing we understand you accept the use of such technology. For more information visit our cookies policy Find out more

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close